NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









EpiBiologics

EpiBiologics

Private
San Mateo, CaliforniaHealthcare & Life Scienceshttps://www.epibiologics.com/

Last Round

Series B

Jan 8, 2026

Total Funding Raised

$310M

Company Overview

EpiBiologics is a biotechnology company that develops protein degradation therapeutics aimed at addressing the root causes of disease biology through antibody-based targeted therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

protein degradationbispecific antibodyoncologytargeted protein degradationTPDcancer therapytissue-selective therapybiotechdrug discoveryclinical-stage biotechEGFR-driven tumorsprotein degraderbiopharmasolid tumor treatmentantibody engineering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EpiBiologics Comps

Public and private peers based on sector, stage, and business model.

EpiBiologics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

EpiBiologics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 8, 2026
Series BJan 8, 2024
Series A ExtensionJul 20, 2023
Series AMar 22, 2023

Key People

Founding team and executive leadership

Ann Lee-Karlon

CEO, President, And Board Member

Executive Team

Aaron Mishel

Chief Financial Officer

Executive Team

Craig Lichtenstein

Chief Operating Officer

Executive Team

EpiBiologics Investors

Notable investors and investment history

EpiBiologics investors
InvestorRounds
Avego ManagementSeries B
Codon CapitalSeries B, Series A, Series A Extension
GVSeries B, Series A Extension, Series A
Digitalis VenturesSeries B, Series A Extension, Series A
Taiho VenturesSeries B, Series A Extension, Series A
Mubadala CapitalSeries A
Mission BioCapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 8, 2026

    Developing an experimental protein-destroying antibody for clinical trials.

  • Jan 8, 2024

    $107M round raised

EpiBiologics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

EpiBiologics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about EpiBiologics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Mateo, California
Employee Range50
Year Founded2022
Last FundingJan 8, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.